BioTheryX Appoints Professor Yinon Ben-Neriah, M.D., Ph.D., to its Scientific Advisory Board

Accomplished scientist who created BioTheryX's promising lead clinical candidate targeting AML adds significant expertise in oncology & immunology to distinguished SAB

News provided by

Biotheryx, Inc.

Mar 06, 2020, 09:05 ET

CHAPPAQUA, N.Y., March 6, 2020 /PRNewswire/ -- BioTheryX, Inc., a clinical stage biotechnology company harnessing the power of protein modulation to treat difficult diseases, today announced the appointment of Professor Yinon Ben-Neriah, M.D., Ph.D., to its distinguished Scientific Advisory Board (SAB) comprised of key opinion leaders in ubiquitin-mediated protein degradation, immunology and oncology. Dr. BenNeriah is Professor of Immunology and Cancer Research at the Lautenberg Center of Immunology of the Hebrew University, Hadassah Medical School in Jerusalem, Israel.

David Stirling, Ph.D., CEO of BioTheryX stated, "As a company dedicated to the development of novel approaches to protein modulation for targeting numerous diseases, we are fortunate to welcome Dr. BenNeriah to our SAB. He and his research team's discovery of BTX-A51 and its unique mechanism of action, potentially inhibiting several key oncogenic targets simultaneously, eradicating leukemic stem cells, and driving activation of the key tumor suppressing oncogene p53, may be one of the most significant innovations in the past 40 years for AML patients and their families."

Dr. Ben-Neriah said, "I am honored and proud to be joining the SAB of BioTheyrX. Having the privilege of interacting with the entire team for the past 5 years, I must say it is truly a visionary company. I believe they are well on their way to improve human health, and hopefully I will be able to contribute to their vision."

Dr. Ben-Neriah received his M.D. from Tel Aviv University and Ph.D. from the Weizmann Institute of Science, and was a postdoctoral fellow in Nobel Laureate Dr. David Baltimore's lab at the Whitehead Institute-MIT. His research work focuses on signaling pathways regulating innate immunity and inflammation, particularly in the context of cancer. His lab deciphered key steps in the activation of the NFkB and Wnt signaling pathways and studied them in animal models of cancer. Dr. Ben-Neriah is an elected member of the European Molecular Biology Organization (EMBO), a spokesman of the International German Israeli Graduate Student program SignGene, Chair of the advisory board of the BIOSS Excellence Center of Freiburg University (Germany), and Adjunct Professor in Shanghai Jiao Tong University.

In December 2019, Dr. Ben-Neriah was awarded the EMET Prize, also known as 'Israel's Nobel Prize', in the Life Sciences category for his "important scientific contribution to understanding immune signaling processes and decoding abnormal signal transmission mechanisms in cancer cells". In addition to this prestigious honor, Dr. Ben-Neriah has also been awarded the Rappaport Prize, for his biomedical research; Columbia University's Schaefer Research Scholar Award; the Teva Founders Prize, and the Landau Prize.

About BioTheryX
BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis, including protein degradation and modulation, and multi-kinase inhibition to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases. Our principal technology platform centers on targeted protein degradation, as well as PHM^® 'molecular glues' that enable the design of small molecules to regulate protein equilibrium. This technology utilizes the body's own protein disposal system to selectively degrade and remove disease-causing proteins. It has potential applicability to a broad range of diseases, including targets that have to date been considered 'undruggable'.

SOURCE Biotheryx, Inc.